IP Library Granted Patent US 11,396,540
Granted Patent B1
US 11,396,540 · App. 16/564,642 · Granted Jul 26, 2022

Methods for making recombinant proteins

Inventor: Elzbieta Wiktoria Puchacz (Pleasanton, CA)
Assignee: Coherus Biosciences, Inc.
C07K16/241A61K39/395C12N5/0018C12P21/00C07K2317/14C07K2317/41C12N2330/50C12N2500/32C12N2500/34C12N2501/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,396,540
App. No.
16/564,642
Granted
Jul 26, 2022
Kind
B1
Abstract

The present invention provides methods and compositions for making proteins, preferably antibodies, more preferably anti-tumor necrosis factor alpha antibodies, and most preferably adalimumab. The present invention further provides methods and compositions for mammalian cell culture, preferably Chinese Hamster Ovary cells.

Claims (22)

1. A liquid culture medium comprising:

about 0.1 to about 0.9 grams/liter glucose; and

at least one hexose selected from the group consisting of galactose, mannose, fructose, maltose, or a combination thereof, each at a concentration of about 0.1 to about 20 grams/liter.

2. The liquid culture medium of claim 1 , wherein the liquid culture medium is a chemically-defined liquid culture medium.

3. The liquid culture medium of claim 1 , wherein the liquid culture medium is an animal-derived component-free liquid culture medium.

4. The liquid culture medium of claim 1 , wherein the liquid culture medium is a serum-free liquid culture medium.

5. The liquid culture medium of claim 1 , wherein the liquid culture medium is a serum-containing liquid culture medium.

6. The liquid culture medium of claim 1 , wherein the liquid culture medium further comprises L-glutamine.

7. The liquid culture medium of claim 1 , wherein the liquid culture medium further comprises insulin growth factor 1 (IGF1).

8. The liquid culture medium of claim 1 , wherein the liquid culture medium further comprises L-glutamine and IGF1.

9. The liquid culture medium of claim 1 , wherein the liquid culture medium comprises at least one hexose selected from the group consisting of galactose, mannose, fructose, or a combination thereof, each at a concentration of about 0.1 g/L to about 20 g/L.

10. The liquid culture medium of claim 9 , wherein the liquid culture medium comprises galactose, mannose, and fructose, each at a concentration of about 0.1 g/L to about 20 g/L.

11. The liquid culture medium of claim 10 , wherein the liquid culture medium further comprises L-glutamine.

12. The liquid culture medium of claim 11 , wherein the liquid culture medium further comprises IGF1.

13. The liquid culture medium of claim 1 , wherein the liquid culture medium comprises mannose at a concentration of about 0.1 g/L to about 20 g/L.

14. The liquid culture medium of claim 13 , wherein the liquid culture medium further comprises L-glutamine.

15. The liquid culture medium of claim 14 , wherein the liquid culture medium further comprises IGF1.

16. The liquid culture medium of claim 1 , wherein the liquid culture medium comprises maltose at a concentration of 0.1 g/L to about 20 g/L.

17. The liquid culture medium of claim 16 , wherein the liquid culture medium further comprises L-glutamine.

18. The liquid culture medium of claim 1 , wherein the liquid culture medium comprises mannose and maltose, each at a concentration of about 0.1 g/L to about 20 g/L.

19. The liquid culture medium of claim 18 , wherein the liquid culture medium further comprises L-glutamine.

20. The liquid culture medium of claim 19 , wherein the liquid culture medium further comprises IGF1.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2024
From: COHERUS BIOSCIENCES, INC.
To: HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD.
Reel/Frame 069084/0884 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 59436/0055 Recorded May 9, 2024
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: COHERUS BIOSCIENCES, INC.; COHERUS INTERMEDIATE CORP.; INTEKRIN THERAPEUTICS INC.
Reel/Frame 067378/0256 →
SECURITY INTEREST Recorded May 8, 2024
From: COHERUS BIOSCIENCES, INC.; COHERUS INTERMEDIATE CORP.; INTEKRIN THERAPEUTICS INC.; SURFACE ONCOLOGY, LLC; COHERUS ONCOLOGY SUPPORTIVE CARE LLC
To: ANKURA TRUST COMPANY, LLC
Reel/Frame 067348/0160 →
SECURITY INTEREST Recorded Mar 18, 2022
From: COHERUS BIOSCIENCES, INC.; COHERUS INTERMEDIATE CORP.; INTEKRIN THERAPEUTICS INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 059436/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2020
From: PUCHACZ, ELZBIETA WIKTORIA
To: COHERUS BIOSCIENCES, INC.
Reel/Frame 053875/0711 →
Continuity (2)
Continuation 14845440 · Sep 4, 2015
Provisional Application 62046496 · Sep 5, 2014